
|Articles|November 6, 2012
NovaBay receives $2.6M to advance Aganocide research
NovaBay Pharmaceuticals has received $2.6 million from partner Galderma for the clinical advancement of NovaBay’s “non-antibiotic, anti-infective” Aganocide compound NVC-422, a topical formulation for impetigo treatment.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
KT-621 Produces 98% STAT6 Degradation in AD Patients
2
Transparency Gaps in Prior Authorization Denials and Their Impact on Dermatologic Care
3
AI at the Bedside: How Automated Solutions are Transforming Vitiligo Management
4
Celebrating a Year of Growth and Research
5



















